Combined immunomodulator and antimicrobial therapy eliminates polymicrobial sepsis and modulates cytokine production in combined injured mice.

Abstract

PURPOSE:

A combination therapy for combined injury (CI) using a non-specific immunomodulator, synthetic trehalose dicorynomycolate and monophosphoryl lipid A (STDCM-MPL), was evaluated to augment oral antimicrobial agents, levofloxacin (LVX) and amoxicillin (AMX), to eliminate endogenous sepsis and modulate cytokine production.

MATERIALS AND METHODS:

Female B6D2F(1)/J mice received 9.75 Gy cobalt-60 gamma-radiation and wound. Bacteria were isolated and identified in three tissues. Incidence of bacteria and cytokines were compared between treatment groups.

RESULTS:

Results demonstrated that the lethal dose for 50% at 30 days (LD(50/30)) of B6D2F(1)/J mice was 9.42 Gy. Antimicrobial therapy increased survival in radiation-injured (RI) mice. Combination therapy increased survival after RI and extended survival time but did not increase survival after CI. Sepsis began five days earlier in CI mice than RI mice with Gram-negative species predominating early and Gram-positive species increasing later. LVX plus AMX eliminated sepsis in CI and RI mice. STDCM-MPL eliminated Gram-positive bacteria in CI and most RI mice but not Gram-negative. Treatments significantly modulated 12 cytokines tested, which pertain to wound healing or elimination of infection.

CONCLUSIONS:

Combination therapy eliminates infection and prolongs survival time but does not assure CI mouse survival, suggesting that additional treatment for proliferative-cell recovery is required.

• Authors: Thomas B Elliott, David L Bolduc, G David Ledney, Juliann G Kiang, Oluseyi O Fatanmi, Stephen Y Wise, Patricia L P Romaine, Victoria L Newman, Vijay K Singh
• Journal: International journal of radiation biology (Int J Radiat Biol) Vol. 91 Issue 9 Pg. 690-702 ( 2015) ISSN: 1362-3095 [Electronic] England
• PMID: 25994812 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Infective Agents
• Chemokines
• Cord Factors
• Cytokines
• Growth Substances
• Immunologic Factors
• Lipid A
• Levofloxacin
• Amoxicillin
• 6,6'-dicorynomycolyl trehalose
• monophosphoryl lipid A

Topics

• Amoxicillin (administration & dosage)
• Animals
• Anti-Infective Agents (administration & dosage)
• Bacterial Infections (drug therapy, immunology, microbiology)
• Chemokines (biosynthesis)
• Cord Factors (administration & dosage)
• Cytokines (biosynthesis)
• Disease Models, Animal
• Drug Therapy, Combination
• Female
• Gamma Rays (adverse effects)
• Growth Substances (biosynthesis)
• Immunologic Factors (administration & dosage)
• Levofloxacin (administration & dosage)
• Lipid A (administration & dosage, analogs & derivatives)
• Mice
• Radiation Injuries, Experimental (drug therapy, immunology, microbiology)
• Sepsis (drug therapy, immunology, microbiology)
• Skin (injuries)
• Wound Infection (drug therapy, immunology, microbiology)